Optieum Biotechnologies
↗Toon, Japan
Optieum Biotechnologies is a clinical-stage-ready biotechnology company focused on discovering and developing innovative CAR-T cell therapies for solid tumors and hematological malignancies. The company utilizes its proprietary 'Eumbody System,' a CAR discovery engine that optimizes the binding domain (scFv) of CAR constructs to enhance immune cell function, proliferation, and longevity.
Headquartered in Japan with a global leadership team, Optieum aims to overcome the limitations of traditional CAR-T therapies in solid tumors, such as the immunosuppressive microenvironment and antigen escape. Their lead programs target high-value antigens like FAPα to disrupt tumor stroma and directly eliminate malignant cells.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$50M+
Investors:Saisei Ventures, Keio Innovation Initiative, ANRI, Real Tech Fund, Iyogin Capital, Zeon Corporation, Kobe University Capital, UntroD Capital
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical (IND-enabling)
Modalities:Cell therapy, CAR-T, CAR-NK
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Daiichi Sankyo (Research collaboration), National Cancer Center Japan (Solid tumor joint research), GI CELL (CAR-NK license and option agreement), Genezen (CDMO for lentiviral vectors), Cellipont Bioservices (Manufacturing partner)
COMPETITION
Position:Emerging
Competitors:Caribou Biosciences, Allogene Therapeutics, Fate Therapeutics, iCell Gene Therapeutics
LEADERSHIP
Key Executives:
Shun Nishioka - President & CEO
Dr. Dan MacLeod - CSO
Dr. Stewart Craig - CTO
Scientific Founders:Dr. Toshiki Ochi (Ehime University)
Board Members:Jonathan Yeh (Saisei Ventures), Yuto Torii (Keio Innovation Initiative), Yusuke Miyazaki (ANRI)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Optieum Biotechnologies. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.